REG - Abbott Laboratories - Abbott 4Q15 Earnings Results <Origin Href="QuoteRef">ABT.N</Origin> - Part 2
- Part 2: For the preceding part double click ID:nRSb3264Na
1,135
Taxes on Earnings from Continuing Operations 135 68 203
Net Earnings from Continuing Operations 695 237 932
Diluted Earnings per Share from Continuing Operations $0.46 $0.16 $0.62
Specified items reflect intangible amortization expense of $143 million and
other expenses of $162 million, primarily associated with cost reduction
initiatives and acquisitions.
4Q14
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization $163 ($163) --
Gross Margin 2,856 191 $3,047 56.9%
R&D 361 (19) 342 6.4%
SG&A 1,666 (86) 1,580 29.5%
Net loss on extinguishment of debt 18 (18) --
Other (Income) Expense, Net 12 (1) 11
Earnings from Continuing Operations before taxes 804 315 1,119
Taxes on Earnings from Continuing Operations 170 6 176
Net Earnings from Continuing Operations 634 309 943
Diluted Earnings per Share from Continuing Operations $0.41 $0.21 $0.62
Specified items reflect intangible amortization expense of $163 million and
other expenses of $152 million, primarily associated with cost reduction
initiatives and deal and other expenses related to acquisitions, as well as
tax expense of $175 million associated with a one-time repatriation of 2014
ex-U.S. earnings, partially offset by favorability as a result of the
resolution of various tax positions and adjustment of tax uncertainties from
prior years.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information From Continuing Operations
Fiscal Year Ended December 31, 2015 and 2014
(in millions, except per share data)
(unaudited)
12M15
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization $601 ($601) --
Gross Margin 11,057 755 $11,812 57.9%
R&D 1,405 (85) 1,320 6.5%
SG&A 6,785 (272) 6,513 31.9%
Other (Income) Expense, Net (281) 288 7
Earnings from Continuing Operations before taxes 3,183 824 4,007
Taxes on Earnings from Continuing Operations 577 172 749
Net Earnings from Continuing Operations 2,606 652 3,258
Diluted Earnings per Share from Continuing Operations $1.72 $0.43 $2.15
Specified items reflect intangible amortization expense of $601 million and
other expenses of $510 million, primarily associated with cost reduction
initiatives and acquisitions, partially offset by a gain on the sale of a
portion of Abbott's position in Mylan stock of $207 million and a decrease in
the fair value of contingent consideration related to a business acquisition.
12M14
As Specified As % to
Reported Items Adjusted Sales
(GAAP)
Intangible Amortization $555 ($555) --
Gross Margin 10,474 721 $11,195 55.3%
R&D 1,345 (72) 1,273 6.3%
SG&A 6,530 (367) 6,163 30.4%
Net loss on extinguishment of debt 18 (18) --
Other (Income) Expense, Net 14 (9) 5
Earnings from Continuing Operations before taxes 2,518 1,187 3,705
Taxes on Earnings from Continuing Operations 797 (130) 667
Net Earnings from Continuing Operations 1,721 1,317 3,038
Diluted Earnings per Share from Continuing Operations $1.12 $0.86 $1.98
Specified items reflect intangible amortization expense of $555 million and
other expenses of $632 million, primarily associated with cost reduction
initiatives and deal and other expenses related to acquisitions, as well as
tax expense of $440 million associated with a one-time repatriation of 2014
ex-U.S. earnings, partially offset by favorability as a result of the
resolution of various tax positions and adjustment of tax uncertainties from
prior years.
RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS
A reconciliation of the fourth-quarter tax rates for continuing operations for
2015 and 2014 is shown below:
4Q15
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $830 $135 16.3%
Specified items 305 68
Excluding specified items $1,135 $203 17.9% 1)
4Q14
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $804 $170 21.1% 2)
Specified items 315 6
Excluding specified items $1,119 $176 15.7% 1)
1) Fourth-quarter 2014 and 2015 tax rates include the year-to-date impact of U.S. tax legislation passed in Dec. 2014 and 2015, respectively, including the R&D tax credit.
2) Reported tax rate on a GAAP basis includes the impact of tax expense of $175 million associated with a one-time repatriation of 2014 ex-U.S. earnings, partially offset by favorability of $133 million as a result of the resolution of various tax positions and adjustment of tax uncertainties from prior years.
A reconciliation of the full-year tax rates for continuing operations for 2015
and 2014 is shown below:
12M15
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $3,183 $577 18.1%
Specified items 824 172
Excluding specified items $4,007 $749 18.7% 3)
12M14
($ in millions) Pre-Tax Taxes on Tax
Income Earnings Rate
As reported (GAAP) $2,518 $797 31.7% 4)
Specified items 1,187 (130)
Excluding specified items $3,705 $667 18.0% 3)
3) Full-year 2014 and 2015 tax rates include the impact of U.S. tax legislation passed in Dec. 2014 and 2015, respectively, including the R&D tax credit.
4) Reported tax rate on a GAAP basis includes the impact of tax expense of $440 million associated with a one-time repatriation of 2014 ex-U.S. earnings, partially offset by favorability of $126 million as a result of the resolution of various tax positions and adjustment of tax uncertainties from prior years.
CONTACT: Abbott Financial: Scott Leinenweber, (224) 668-0791, Michael Comilla,
(224) 668-1872, Jeffrey Byrne, (224) 668-8808; or Abbott Media: Scott Stoffel,
(224) 668-5201, Elissa Maurer, (224) 668-3309
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on Abbott Laboratories
See all newsREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG - Takeover Panel - Disclosure Table
Announcement